Ari Breiner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4897231/publications.pdf

Version: 2024-02-01

430874 454955 1,063 68 18 30 h-index citations g-index papers 1105 68 68 68 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Epidemiology of myasthenia gravis in Ontario, Canada. Neuromuscular Disorders, 2016, 26, 41-46.	0.6	90
2	Comparison of sensitivity and specificity among 15 criteria for chronic inflammatory demyelinating polyneuropathy. Muscle and Nerve, 2014, 50, 40-46.	2.2	82
3	Reference values for ultrasonograpy of peripheral nerves. Muscle and Nerve, 2016, 53, 538-544.	2.2	66
4	Indications for neuromuscular ultrasound: Expert opinion and review of the literature. Clinical Neurophysiology, 2018, 129, 2658-2679.	1.5	65
5	Peripheral nerve highâ€resolution ultrasound in diabetes. Muscle and Nerve, 2017, 55, 171-178.	2.2	64
6	Incat disability score: A critical analysis of its measurement properties. Muscle and Nerve, 2014, 50, 164-169.	2.2	41
7	Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45Âg/L: a systematic review. Journal of Neurology, 2019, 266, 616-624.	3.6	41
8	Updated cerebrospinal fluid total protein reference values improve chronic inflammatory demyelinating polyneuropathy diagnosis. Muscle and Nerve, 2019, 60, 180-183.	2.2	37
9	Laser Doppler Flare Imaging and Quantitative Thermal Thresholds Testing Performance in Small and Mixed Fiber Neuropathies. PLoS ONE, 2016, 11, e0165731.	2.5	33
10	The Characteristics of Chronic Inflammatory Demyelinating Polyneuropathy in Patients with and without Diabetes – An Observational Study. PLoS ONE, 2014, 9, e89344.	2.5	29
11	Peripheral Nerve Ultrasound in Small Fiber Polyneuropathy. Ultrasound in Medicine and Biology, 2015, 41, 2820-2826.	1.5	28
12	Repetitive nerve stimulation cutoff values for the diagnosis of myasthenia gravis. Muscle and Nerve, 2017, 55, 166-170.	2.2	27
13	The utility of a single simple question in the evaluation of patients with myasthenia gravis. Muscle and Nerve, 2018, 57, 240-244.	2.2	27
14	Causes of albuminocytological dissociation and the impact of age-adjusted cerebrospinal fluid protein reference intervals: a retrospective chart review of 2627 samples collected at tertiary care centre. BMJ Open, 2019, 9, e025348.	1.9	26
15	Economic Costs of Myasthenia Gravis: A Systematic Review. Pharmacoeconomics, 2020, 38, 715-728.	3.3	22
16	Comparison of diabetes patients with "demyelinating―diabetic sensorimotor polyneuropathy to those diagnosed with <scp>CIDP</scp> . Brain and Behavior, 2013, 3, 656-663.	2.2	21
17	The sensitivity and specificity of the neurological examination in polyneuropathy patients with clinical and electrophysiological correlations. PLoS ONE, 2017, 12, e0171597.	2.5	21
18	Canadian Administrative Health Data Can Identify Patients with Myasthenia Gravis. Neuroepidemiology, 2015, 44, 108-113.	2.3	20

#	Article	IF	Citations
19	Validation of cooling detection threshold as a marker of sensorimotor polyneuropathy in type 2 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 716-722.	2.3	20
20	Adult CSF total protein: Higher upper reference limits should be considered worldwide. A web-based survey. Journal of the Neurological Sciences, 2019, 396, 48-51.	0.6	20
21	Electrophysiological testing is correlated with myasthenia gravis severity. Muscle and Nerve, 2017, 56, 445-448.	2.2	19
22	Peripheral Nerve Ultrasound Imaging Shows Enlargement of Peripheral Nerves Outside the Brachial Plexus in Neuralgic Amyotrophy. Journal of Clinical Neurophysiology, 2016, 33, e31-e33.	1.7	18
23	Frequent laboratory abnormalities in CIDP patients. Muscle and Nerve, 2016, 53, 862-865.	2.2	18
24	Muscle biopsy technical safety and quality using a self-contained, vacuum-assisted biopsy technique. Neuromuscular Disorders, 2018, 28, 450-453.	0.6	14
25	Measurement of Cooling Detection Thresholds for Identification of Diabetic Sensorimotor Polyneuropathy in Type 1 Diabetes. PLoS ONE, 2014, 9, e106995.	2.5	14
26	Ultrasound in Neuromuscular Disorders. Journal of Clinical Neurophysiology, 2016, 33, 80-85.	1.7	13
27	Clinical characteristics, and impairment and disability scale scores for different CIDP Disease Activity Status classes. Journal of the Neurological Sciences, 2017, 372, 223-227.	0.6	13
28	Uric acid levels correlate with the severity of diabetic sensorimotor polyneuropathy. Journal of the Neurological Sciences, 2017, 379, 94-98.	0.6	12
29	Edaravone for amyotrophic lateral sclerosis: barriers to access and lifeboat ethics. Cmaj, 2020, 192, E319-E320.	2.0	12
30	Disease activity in chronic inflammatory demyelinating polyneuropathy. Journal of the Neurological Sciences, 2016, 369, 204-209.	0.6	11
31	Temporal evolution of nerve conduction study abnormalities in antiâ€myelinâ€associated glycoprotein neuropathy. Muscle and Nerve, 2021, 63, 401-404.	2.2	10
32	Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy Management. Canadian Journal of Neurological Sciences, 2022, 49, 7-18.	0.5	9
33	Genetic testing for amyotrophic lateral sclerosis in Canada – an assessment of current practices. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-8.	1.7	9
34	Treatment Responsiveness in CIDP Patients with Diabetes Is Associated with Higher Degrees of Demyelination. PLoS ONE, 2015, 10, e0139674.	2.5	9
35	Characteristics of muscle cramps in patients with polyneuropathy. Neuromuscular Disorders, 2014, 24, 671-676.	0.6	8
36	Elevated Vibration Perception Thresholds in CIDP Patients Indicate More Severe Neuropathy and Lower Treatment Response Rates. PLoS ONE, 2015, 10, e0139689.	2.5	8

#	Article	IF	CITATIONS
37	The median to ulnar cross-sectional surface area ratio in carpal tunnel syndrome. Clinical Neurophysiology, 2018, 129, 2239-2244.	1.5	7
38	Age matters. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e576.	6.0	7
39	Quantitative sonographic assessment of myotonia. Muscle and Nerve, 2018, 57, 146-149.	2.2	7
40	Repetitive facial nerve stimulation in myasthenia gravis 1min after muscle activation is inferior to testing a second muscle at rest. Clinical Neurophysiology, 2016, 127, 3294-3297.	1.5	6
41	Selective or predominant triceps muscle weakness in African–American patients with myasthenia gravis. Neuromuscular Disorders, 2017, 27, 646-649.	0.6	6
42	Ultrasound-Assisted Lumbar Puncture in a Neuromuscular Clinic has a High Success Rate and Less Pain. Canadian Journal of Neurological Sciences, 2019, 46, 79-82.	0.5	6
43	Laryngospasm in amyotrophic lateral sclerosis. Muscle and Nerve, 2022, 65, 400-404.	2.2	6
44	Impact of disuse muscular atrophy on the compound muscle action potential. Muscle and Nerve, 2020, 61, 58-62.	2.2	5
45	Myasthenia gravis. Cmaj, 2018, 190, E1141-E1141.	2.0	4
46	Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	4
47	Idiopathic respiratory synkinesis: A case series. Muscle and Nerve, 2020, 61, E8-E9.	2.2	4
48	Laboratory Abnormalities in Polyneuropathy and Electrophysiological Correlations. Canadian Journal of Neurological Sciences, 2018, 45, 346-349.	0.5	3
49	Autologous Hematopoietic Stem Cell Transplantation for Chronic Inflammatory Demyelinating Polyradiculoneuropathy. Canadian Journal of Neurological Sciences, 2021, , 1-7.	0.5	3
50	Thyrotoxicosis Resulting in Unilateral Upper Limb Chorea and Ballismus. Canadian Journal of Neurological Sciences, 2021, , 1-2.	0.5	3
51	A Survey of Cerebrospinal Fluid Total Protein Upper Limits in Canada: Time for an Update?. Canadian Journal of Neurological Sciences, 2019, 46, 283-286.	0.5	2
52	Distal Cervical Spondylotic Amyotrophy: Case Reports Demonstrating Clinical/Imaging Segmental Discrepancy. Journal of Clinical Neuromuscular Disease, 2019, 21, 107-111.	0.7	2
53	Fracture Risk in Patients with Myasthenia Gravis: A Population-Based Cohort Study. Journal of Neuromuscular Diseases, 2021, 8, 625-632.	2.6	2
54	Response to Comment on Breiner et al. Does the Prevailing Hypothesis That Small-Fiber Dysfunction Precedes Large-Fiber Dysfunction Apply to Type 1 Diabetic Patients? Diabetes Care 2014;37:1418–1424. Diabetes Care, 2014, 37, e242-e242.	8.6	1

#	Article	IF	CITATIONS
55	Fulminant Strokes Secondary to Radiation-induced Small-vessel Arteriopathy. Brain Impairment, 2014, 15, 58-60.	0.7	1
56	Quinine and leg cramps. Cmaj, 2015, 187, 757.1-757.	2.0	1
57	Clinical Reasoning: A case of subacute cognitive decline in a 76-year-old man. Neurology, 2016, 87, e124-e128.	1.1	1
58	Connecting the Dots. New England Journal of Medicine, 2017, 377, 978-984.	27.0	1
59	Teaching Video Neurolmages: Rippling muscle disease with caveolin myopathy. Neurology, 2018, 91, e1726-e1727.	1.1	1
60	Intermittent undulating tongue as an involuntary movement in early amyotrophic lateral sclerosis. Parkinsonism and Related Disorders, 2019, 67, 1-2.	2.2	1
61	Ultrasound in Multifocal Motor Neuropathy: Clinical and Electrophysiological Correlations. Journal of Clinical Neuromuscular Disease, 2019, 20, 165-172.	0.7	1
62	Myofibrillar Myopathy Mimicking Polyneuropathy. Case Reports in Neurology, 2020, 12, 97-102.	0.7	1
63	Intraneural Ganglion Cysts of the Fibular Nerve: A Cause of Fluctuating Painful Foot Drop. Canadian Journal of Neurological Sciences, 2018, 45, 601-603.	0.5	0
64	Cerebrospinal Fluid in Posterior Reversible Encephalopathy Syndrome. Neurohospitalist, The, 2019, 9, 125-125.	0.8	0
65	Dataset for worldwide survey of cerebrospinal total protein upper reference values. Data in Brief, 2019, 23, 103760.	1.0	0
66	Vertebral Ischemic Necrosis in Diabetic Lumbosacral Radiculoplexus Neuropathy. Diabetes Care, 2021, 44, e53-e54.	8.6	0
67	Does Diabetes Alter CSF Total Protein Levels? A Retrospective Cohort Study. Neurohospitalist, The, 0, , 194187442110393.	0.8	0
68	MuSK not MNGIE: Atypical MuSK-antibody myasthenia presenting as a genetic disorder. Neuromuscular Disorders, 2021, , .	0.6	0